10月17日,国家药品监督管理局发布消息,四川科伦博泰生物医药股份有限公司(简称“科伦博泰”)申报的注射用博度曲妥珠单抗(商品名:舒泰莱)获批上市,用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。乳腺癌作为一种常见的恶性肿瘤,严重威胁女性健康。有数据显示,HER2阳性乳腺癌约占所有乳腺癌患者的15%—20%,是一种具有侵袭性和高度恶性的亚型。而科伦博泰...
Source Link10月17日,国家药品监督管理局发布消息,四川科伦博泰生物医药股份有限公司(简称“科伦博泰”)申报的注射用博度曲妥珠单抗(商品名:舒泰莱)获批上市,用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。乳腺癌作为一种常见的恶性肿瘤,严重威胁女性健康。有数据显示,HER2阳性乳腺癌约占所有乳腺癌患者的15%—20%,是一种具有侵袭性和高度恶性的亚型。而科伦博泰...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.